ViraTherapeutics GmbH

ViraTherapeutics GmbH is a privately held biopharmaceutical company that is developing promising innovative virus-based immunotherapeutics for the treatment of cancer. ViraT was founded in 2013 as a spin-out of the Medical University of Innsbruck, (Austria), by Prof. Dr. Dorothee von Laer, head of the Virology Division at the University.
ViraT develops oncolytic cancer vaccines based on a chimeric virus derived from the Vesicular Stomatitis Virus (VSV) called VSV-GP. VSV-GP has proved to be safe and highly effective in a broad range of pre-clinical cancer models. It has also been shown to be effective upon repeated application, which is unique among vector vaccines and therapeutic viruses.

Details


Adresse:
ViraTherapeutics GmbH

Exlgasse 20a
6020 Innsbruck (Österreich)
Österreich
Arbeitsgebiet:
Klinische Forschung
Forschung & Entwicklung
Produktion
Expansion:
national
Mitarbeiteranzahl:
11-50
Gründungsjahr:
2013